Gafisa SA (ADR) (NYSE:GFA)’s shares are up by 5.91% – GOL, HEB

Northern, WI 04/09/2013 (usastockreport) – Gafisa SA (ADR) (NYSE:GFA) is currently trading at $4.48 which is up by 5.91%. It previously closed at $4.23 and opened this morning at $4.14. The daily range of the stock has been $4.129 – $4.25 with a 52 week range of $2.05 -$5.24. The market capitalization is $913.93 million with 862,240 shares outstanding and an average volume of 2,024,540. The earnings per share is -.28 and the beta of the stock is 2.36. Gafisa S.A. is a company that builds homes, buildings, gums, and parking structures in Brazil. In the past year the company’s stock has been doing pretty well, only experiencing a drastic decrease in price per shares in mid-summer. In the past three months the stock has also taken a bit of a decrease as well in mid-February and has yet to recover from that.

GOL Linhas (NYSE:GOL) is company that provides air transportation for cargo, mailbags and passengers in Latin America. Currently the price per share is trading at $5.83 which is up 9.59%. The stock opened at $6.03 with its previous close price at $5.32. The daily range is $5.75 -$6.03 and the 52 week range is $3.77 – $7.67. The market capitalization is $1.61 billion with 2,826,697 shares outstanding. Today GOL Linhas announced they would enter into an investment agreement with General Atlantic which will total to be 400 million dollars. Under these investment conditions General Atlantic is not able to sell the shares for at least 9 months after the agreement.

Hemispherx Biopharma Inc (NYSE:HEB) is currently up by 3.40% trading at a price per share of 0.240. The previously closed at $.23 and opened this morning at $.24. The 52 week range of the stock has been $.18 – $1.10 per share with a market capitalization of $42.28 million and 2,347,830 shares outstanding. The earnings per share is -.12 with a beta of the stock at 1.96 and an average volume of 1,411,140 shares. Hemispherx Biopharma develop new drug therapies that are based on the immune system. The recent outbreak of the avian flu in China has benefited Hemispherx Biopharma stock, rising 15% since the announcement of the virus.

Like it? Share it!

Leave A Response